JNNP: Serum IgG anti-GD1a antibodies and mEGOS predict the prognosis of Green-Barre syndrome.

Guillain-Barre syndrome (GBS), also known as Greenbari syndrome, is an autoimmune peripheral neuropathy characterized by demyelination of peripheral nerves and nerve roots and small angioarthritis cell immersion, and is called acute inflammatory demyelinative multiple neuropathy (AIDP) by typical GBS, which is clinically characterized by acute symmetrical flaccid limb paralysis.
about 15% to 20% of people with Green-Barre syndrome (GBS) were unable to walk independently within 6 months of developing neurological symptoms.
improved Erasmus-GBS Prognoste Score (mEGOS) has been reported as a prognosm tool.
, the authors looked at the relationship between poor prognosis, inability to walk independently at 6 months, and anti-neural glycoside antibodies.
methods: Retrospective collection of clinical and serological data from 177 GBS patients in Japan, to explore the relationship between prognosis and serum anti-neurotic glycosides (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a) antibodies.
, the combined application of serum IgG antibodies between mEGOS and anti-neurososide lipids was also studied to help predict poor prognosis.
results: The IgG anti-GD1a antibody group had a poor prognostic difference compared to the non-IgG antibody group (9 out of 25 cases (36%), 8 out of 127 cases (6%), p.lt;0.001.
, 80% of patients had serum IgG anti-GD1a antibodies and high mEGOS≥10 on the 7th day of hospitalization, with poor prognosis.
conclusion: Serum IgG anti-GD1a antibody and high mEGOS combined application can be more accurate than pure mEGOS prediction of prognosis, especially for adverse prognosis prediction.
Yamagishi Y, Kuwahara M, Suzuki H, et al IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome journal of Neurology, Neurosurgery and Psimsy Published Online First: 11 October 2020. doi: 10.1136/jnnp-2020-323960MedSci Original Source: M edSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medicine and are not reproduced by any media, website or individual without authorization, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.